Roche and AnaptysBio pair up to discover new antibodies
This article was originally published in Scrip
Executive Summary
Roche and privately held AnaptysBio have agreed to develop antibody therapeutics using the smaller firm's proprietary somatic hypermutation platform. Financial terms of the deal were not disclosed.